26345-15-3

Upstream product

• 855651-19-3 1-ethoxy-5,6,7,8-tetrahydro-isoquinoline 
• 119-65-3 isoquinoline 
• 1532-72-5 isoquinoline N-oxide 
• 1532-97-4 4-bromoisoquinoline 
• 1532-84-9 isoquinolin-1-ylamine 
• 66728-96-9 1-ethoxyisoquinoline 
• 66728-98-1 4-bromo-1-chloroisoqionoline 
• 3749-21-1 4-bromoisoquinoline N-oxide 
• 59050-62-3 1-ethoxy-[4]isoquinolylamine 
• 59050-59-8 4-bromo-1-ethoxy-isoquinoline 
• 858194-24-8 1-ethoxy-5,6,7,8-tetrahydro-[4]isoquinolylamine 
• 19493-44-8 1-chloroisoquinoline 
• 491-30-5 1-isoquinolone 
• 1297284-55-9 methyl 2-(5-fluoro-3-iodo-2-methyl-1H-indol-1-yl)acetate 

Downstream Products

• 36556-06-6 5,6,7,8-tetrahydroisoquinoline 
• 1297276-94-8 2-(3-(2-benzyl-1-oxo-1,2,5,6,7,8-hexahydroisoquinolin-4-yl)-5-fluoro-2-methyl-1H-indol-1-yl)acetic acid 
• 1297284-56-0 2-benzyl-4-iodo-5,6,7,8-tetrahydroisoquinolin-1(2H)-one 
• 1297284-57-1 2-benzyl-4-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-5,6,7,8-tetrahydroisoquinolin-1(2H)-one 
• 1590409-66-7 C₁₅H₁₄BrNO 
• 1590402-79-1 2-phenyl-4-methyl-5,6,7,8-tetrahydrocyclohexa[c]pyridin-1(2H)-one 
• 1590402-82-6 C₁₉H₁₉N₃O 
• 861136-92-7 (3-methanesulfonyl-phenyl)-(1-methoxy-5,6,7,8-tetrahydro-isoquinolin-4-yl)-amine 
• 861136-91-6 1-[3-(1-methoxy-5,6,7,8-tetrahydro-isoquinolin-4-ylamino)-phenyl]-ethanone 
• 444898-52-6 C₃₅H₃₁NO₈ 

Relevant academic research and scientific papers

A Chiral Phenanthroline Ligand with a Hydrogen-Bonding Site: Application to the Enantioselective Amination of Methylene Groups

A silver-catalyzed amination is reported that occurs at the aliphatic C3-substituent of various quinolones and pyridones. The C-H amination reaction proceeded with high site-and enantioselectivity (14 examples, 83-97% ee). The key to its success is the use of a chiral phenanthroline ligand that is attached via an ethynyl linker to the 8-position of octahydro-1H-4,7-methanoisoindol-1-one. AgPF6 (10 mol %) served as the silver source, PhI.NNs as the nitrene precursor, and 1,10-phenanthroline as the coligand. The reaction outcome can be understood by assuming a nitrene C-H insertion within a hydrogen-bonded silver complex in which a single C-H bond is exposed to the catalytic reaction center.

ANTI-FIBROTIC PYRIDINONES

This application relates to polycyclic compounds with a pyridinone or pyridinone derivative core including, substituted pyridinones, 5,6- and 6,6- bicyclic heterocycles and substituted pyridine-thiones. This application also discloses methods of preparing these polycyclic compounds, pharmaceutical compositions and medicaments comprising said compounds and methods to treat, prevent or diagnose diseases, disorders or conditions associated with fibrosis.

ANTI-FIBROTIC PYRIDINONES

Disclosed are pyridinone compounds, method for preparing these compounds, and methods for treating fibrotic disorders.

Discovery of isoquinolinone indole acetic acids as antagonists of chemoattractant receptor homologous molecule expressed on TH2 cells (CRTH2) for the treatment of allergic inflammatory diseases

Previously we reported the discovery of CRA-898 (1), a diazine indole acetic acid containing CRTH2 antagonist. This compound had good in vitro and in vivo potency, low rates of metabolism, moderate permeability, and good oral bioavailability in rodents. H

INDOLE BASED RECEPTOR CRTH2 ANTAGONISTS

Disclosed are compounds of Formula (I): which are useful as antagonists of the CRTH2 receptors. Pharmaceutical compositions containing compounds of Formula (I) and the use of compounds of Formula (I) to treat diseases or disorders that are responsive to inhibition of the binding of endogenous ligands to the CRTH2 receptor are also disclosed. Methods for preparing and using these compounds are further described.

SUBSTITUTED TETRAHYDRO-2H-ISOQUINOLIN-1-ONE DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF, AND USE OF THE SAME AS MEDICAMENTS

The invention relates to compounds of general formula (I), the designations of the substituents R1, R2, Ar and X being cited in the description, and to the physiologically compatible salts thereof. The invention also relates to a method for producing said compounds, and to the use thereof as medicaments. The inventive compounds are poly(ADP-ribose)polymerase (PARP) inhibitors.

Poly(ADP-ribose) polymerase-1 (PARP-1) inhibitors based on a tetrahydro-1(2H)-isoquinolinone Scaffold: Synthesis, biological evaluation and X-ray crystal structure

The synthesis, activity and physical properties of two series of novel potent tetrahydro-1(2H)-isoquinolinone based PARP-1 inhibitors are described. The new structural classes with a non-planar ring system interact specifically with the PARP-1 protein at the nicotinamide-binding site. Georg Thieme Verlag Stuttgart.

Superacidic activation of 1- and 3-isoquinolinols and their electrophilic reactions

Isomeric 1- and 3-isoquinolinols (11 and 12) when activated in CF3SO3H-SbF5 acid system undergo selective ionic hydrogenation with cyclohexane to give 5,6,7,8-tetrahydro-1(2H)- and 5,6,7,8-tetrahydro-3(2H)-isoquinolinones (22 and 27). Under the influence of aluminum chloride similar products were also obtained along with 3,4-dihydro-1(2H)- and 1,4-dihydro-3(2H)-isoquinolinones (23 and 28), respectively. Compounds 11 and 12 also condense with benzene in the presence of aluminum halides, under mild conditions, to give 3,4-dihydro-3-phenyl-1(2H)- and 1,4-dihydro-1-phenyl-3(2H)-isoquinolinones (24 and 29), respectively. Prolonged reaction time or catalysis under strongly acidic HBr-AlBr3 provides an alternative reaction pathway to yield 5,6-dihydro-6,8-diphenyl-1(2H)- and 5,6,7,8-tetrahydro-6,8-diphenyl-3(2H)-isoquinolinones (25 and 30), respectively. Products 24 and 29 were also found to revert back to 11 and 12 in the presence of aluminum halides in o-dichlorobenzene. The mechanism of these intriguing reactions, which involves superelectrophilic dicationic intermediates, is discussed.